Luya Cheng

469 total citations
29 papers, 319 citations indexed

About

Luya Cheng is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Luya Cheng has authored 29 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 10 papers in Immunology and 7 papers in Oncology. Recurrent topics in Luya Cheng's work include Platelet Disorders and Treatments (11 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Immune Cell Function and Interaction (4 papers). Luya Cheng is often cited by papers focused on Platelet Disorders and Treatments (11 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Immune Cell Function and Interaction (4 papers). Luya Cheng collaborates with scholars based in China, Malaysia and Denmark. Luya Cheng's co-authors include Yunfeng Cheng, Yanxia Zhan, Lili Ji, Boting Wu, Ke Yang, Zhihui Min, Lihua Sun, Clarence Augustine TH Tee, Fanli Hua and Meirong Zhao and has published in prestigious journals such as Blood, Langmuir and European Heart Journal.

In The Last Decade

Luya Cheng

25 papers receiving 319 citations

Peers

Luya Cheng
Petr Čižmár United States
Haruyuki Fujita Japan
Hironobu Anbo Japan
Jorge A. Di Paola United States
Kazuya Koyama Japan
Takeo Iwasaki Japan
Ru Xiang China
Tzu-Chieh Chao Taiwan
Maofang Lin China
Yunjie Wu China
Petr Čižmár United States
Luya Cheng
Citations per year, relative to Luya Cheng Luya Cheng (= 1×) peers Petr Čižmár

Countries citing papers authored by Luya Cheng

Since Specialization
Citations

This map shows the geographic impact of Luya Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luya Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luya Cheng more than expected).

Fields of papers citing papers by Luya Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luya Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luya Cheng. The network helps show where Luya Cheng may publish in the future.

Co-authorship network of co-authors of Luya Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Luya Cheng. A scholar is included among the top collaborators of Luya Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luya Cheng. Luya Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Ziqing, Chengjie Wang, Yongxin Pan, et al.. (2025). Real-IAD D3: A Real-World 2D/Pseudo-3D/3D Dataset for Industrial Anomaly Detection. 15214–15223.
2.
Cheng, Luya, Zhimei Wang, Ling Yuan, et al.. (2025). Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0–1 DLBCL patients. Annals of Hematology. 104(8). 4165–4173. 1 indexed citations
3.
Tan, Hui, Luya Cheng, Ling Yuan, et al.. (2025). Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL. Annals of Hematology. 104(5). 2823–2830.
4.
Sun, Zhenliang, Yuye Shi, Yue Teng, et al.. (2024). Development and validation of prognostic models based on 18F-FDG PET radiomics, metabolic parameters, and clinical factors for elderly DLBCL patients. Annals of Hematology. 103(12). 5583–5598. 4 indexed citations
5.
6.
7.
Ren, Liang, Jiadai Xu, Jing Li, et al.. (2023). A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. Clinical and Experimental Medicine. 23(6). 2583–2591. 5 indexed citations
8.
Xu, Jiadai, Luya Cheng, Ke Yang, et al.. (2023). Effectiveness and Safety of Orelabrutinib Combined with Rituximab As First-Line Treatment in Marginal Zone Lymphoma. Blood. 142(Supplement 1). 6146–6146.
9.
Cao, Jingjing, Lili Ji, Yanxia Zhan, et al.. (2023). MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages. Cellular and Molecular Immunology. 20(12). 1413–1427. 26 indexed citations
10.
11.
Wang, Shuai, Miao Lin, Zhenyang Lin, et al.. (2022). A novel predictive model for distinguishing mediastinal lymphomas from thymic epithelial tumours. European Journal of Cardio-Thoracic Surgery. 62(6). 1 indexed citations
12.
Chen, Pu, Boting Wu, Lili Ji, et al.. (2021). Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms. Frontiers in Medicine. 8. 598182–598182. 11 indexed citations
13.
Zhan, Yanxia, Luya Cheng, Boting Wu, et al.. (2021). Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia. Annals of Translational Medicine. 9(3). 222–222. 15 indexed citations
14.
Wu, Boting, Pu Chen, Fanli Hua, et al.. (2020). Circulating CX3CR1+CD163+ M2 monocytes markedly elevated and correlated with cardiac markers in patients with acute myocardial infarction. Annals of Translational Medicine. 8(9). 578–578. 5 indexed citations
15.
Cheng, Luya, Lili Ji, Feng Li, et al.. (2020). Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia. Thrombosis Research. 190. 11–19. 39 indexed citations
16.
Xu, Jiadai, Tianhong Xu, Wenjing Wang, et al.. (2020). The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides. Leukemia & lymphoma. 61(10). 2351–2364. 12 indexed citations
17.
Cheng, Luya, Feng Li, Lili Ji, et al.. (2019). The abnormal function of CD39+ regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia. Annals of Hematology. 98(8). 1845–1854. 15 indexed citations
18.
Cheng, Luya, Chanjuan Liu, Feng Li, et al.. (2019). The prediction value of Treg cell subtype alterations for glucocorticoid treatment in newly diagnosed primary immune thrombocytopenia patients. Thrombosis Research. 181. 10–16. 24 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Petr Čižmár Breakdown of academic impact, for papers by Haruyuki Fujita Breakdown of academic impact, for papers by Hironobu Anbo Breakdown of academic impact, for papers by Jorge A. Di Paola Breakdown of academic impact, for papers by Kazuya Koyama Breakdown of academic impact, for papers by Takeo Iwasaki Breakdown of academic impact, for papers by Ru Xiang Breakdown of academic impact, for papers by Tzu-Chieh Chao Breakdown of academic impact, for papers by Maofang Lin Breakdown of academic impact, for papers by Yunjie Wu
Rankless by CCL
2026